2.6300
27-十一月-24 16:45:00
15 分钟延时
股票
-0.1400
-5.05%
今日范围
2.6200 - 2.7500
ISIN
N/A
来源
NASDAQ
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 9月 2024 08:30:00 条件 Nasdaq GlobeNewswire